top of page
Search

Research Roundup: Apr 15, 2025

  • Writer: Lex Pelger
    Lex Pelger
  • 12 minutes ago
  • 4 min read


Best of cannabinoid science this week...


In older people using cannabis, they experienced clinically significant improvements in pain, sleep, quality of life & reductions in co-medication plus “the cost per QUALY [quality-adjusted life-year] was well below the standard for traditional pharmaceuticals”

Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes

 

In women with chronic pelvic pain & fibromyalgia, a survey found CBD improved pain, insomnia & anxiety as well as being substituted for at least one other medication

Cannabidiol use and perceptions of effectiveness in women with chronic pelvic pain

 

In healthy adults, comparing the effects of THC vs delta-8 THC

A Within-Subject Cross-Over Trial Comparing the Acute Effects of Oral Delta-8-Tetrahydrocannabinol and Delta-9-Tetrahydrocannabinol in Healthy Adults

 

For Tourette's syndrome, 2 meta-analyses found cannabis caused significant reductions in tic severity & and premonitory urges

Cannabis for Tic Control: A Systematic Review and Meta-analysis of Its Efficacy in Tourette Syndrome Management (P10-5.013)

Evaluating the Efficacy of Cannabis-based Medicines in Managing Tourette Syndrome: A Comprehensive Meta-analysis and Systematic Review (P10-5.027)

 

In young people with Fragile X Syndrome (a genetic disorder of intellectual disability & a wide range of comorbidities), CBD gel caused improvements to scores for irritability & caregiver's impression of change to disruptive behaviors

Long-term Safety and Effectiveness of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Irritability-Related Behavioral Symptoms in Children and Adolescents with Fragile X Syndrome: Update to Open-Label Extension Study (ZYN2-CL-017) (S31.007)

 

For tuberous sclerosis complex (a rare genetic disease of non-cancerous tumor growth, seizures & developmental delays), CBD improved dysregulated behavior & overactivity/impulsivity scores

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorder (TAND) Outcomes Following Add-on Cannabidiol (CBD) Treatment: 3-Month Analysis of Open-Label Phase 3b/4 Trial EpiCom (P8-9.005)

 

In a survey of caregivers for epilepsy, CBD improved seizure duration, the condition of the patient & their own experience

Caregiver-Reported Real-world Use of Cannabidiol (CBD) and Effects on Seizures and Caregiver Burden: Results From the CARE-EpiC Survey (P1-9.003)

And a survey of nurses reported improvements in seizure frequency, emotional functioning, sleep, cognition, communication & physical functioning

Nurse-Reported Outcomes of Cannabidiol (CBD) Treatment in the Long-Term Care (LTC) Setting: Results From the BEhavior, COgnition, and More With Epidiolex® in the Long-Term Care Setting (BECOME-LTC) Survey (P2-9.016)

And in children with severe childhood epilepsies, CBD combined well with the treatment of fenfluramine

Safety, Tolerability, Pharmacokinetics, and Efficacy of Fenfluramine in Combination With Cannabidiol: Results From a Phase 1 Study (P9-9.010)

 

In a case report of non-epileptic myoclonus (disordered tremulous movements) in a person with Angelman syndrome (a rare neuro-genetic disorder of developmental disabilities & nerve symptoms), after the failure of several other medications, CBD caused significant improvements in movements, sleep, the ability to walk without assistance & overall quality of life

Cannabidiol Intervention for Non-epileptic Myoclonus in Angelman Syndrome (P8-5.027)

 

In pharmacy data of people using prescription CBD, an analysis of their dosing regimen

Dosing Patterns and Persistence on Cannabidiol (CBD) – Insights From US Specialty Pharmacy Data (P12-9.005)

 

In this multicenter study of epilepsy, CBD reduced seizures & increased scores on the Clinical Global Impression scale

Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real-world study

 

At an urban pain clinic, cannabis use was associated with lower levels of opioid painkiller use

Medical Cannabis Experience at an Urban Academic Pain Practice (P4-7.001)

“Preferences were highest for equal THC/CBD (42%) or low THC/high CBD (36%) concentrations in tincture (43%) or vape (35%) forms with tolerable side effects.”

 

In a survey of Ecuadorian veterinarians, the majority had a general positive perception of CBD & its therapeutic uses

Evaluating the viability of integrating CBD in the treatment of small species: Study of the perception of veterinarians in the City of Quito


In aging mice with memory impairment & brain inflammation, 7 months of CBD reduced their cognitive decline & inflammatory response

Effects of cannabidiol (CBD) treatments on age-related cognitive decline in C57 mice

 

In diabetic mice, CBD improved blood glucose levels & alleviated their mood & memory deficits by boosting their low levels of anandamide & 2-AG, suppression of the HMGB1-TLR4 pathway & anti-inflammatory effects in the microglia (guardian immune cells of the brain)

Potentiation of endocannabinoid signaling alleviates depressive-like behavior in diabetic mice

 

In a mouse model of Alzheimer's disease, the chronic use of PEA reduced neural inflammation, improved cognitive function, restored dendritic spine density & reduced astrogliosis (an abnormal increase in the number of astrocytes, the most predominant brain support cell)

Chronic palmitoylethanolamide administration via slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer's disease

 

In a mouse model of neuroinflammation, CBD-rich cannabis extract reduced anxiety-like behaviors, cognitive deficits, oxidative stress, inflammation & locomotor impairments better than synthetic CBD

Cannabidiol-Rich Cannabis sativa L. Extract Alleviates LPS-Induced Neuroinflammation Behavioral Alterations, and Astrocytic Bioenergetic Impairment in Male Mice

Comments

bottom of page